857 related articles for article (PubMed ID: 28750737)
1. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS
Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737
[TBL] [Abstract][Full Text] [Related]
2. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
[TBL] [Abstract][Full Text] [Related]
3. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
[TBL] [Abstract][Full Text] [Related]
4. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
[TBL] [Abstract][Full Text] [Related]
5. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Smith S; Waters V; Jahnke N; Ratjen F
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
[TBL] [Abstract][Full Text] [Related]
6. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
Sousa AM; Monteiro R; Pereira MO
Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and Genotypic Adaptations in Pseudomonas aeruginosa Biofilms following Long-Term Exposure to an Alginate Oligomer Therapy.
Oakley JL; Weiser R; Powell LC; Forton J; Mahenthiralingam E; Rye PD; Hill KE; Thomas DW; Pritchard MF
mSphere; 2021 Jan; 6(1):. PubMed ID: 33472983
[TBL] [Abstract][Full Text] [Related]
8. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
Price KE; Orazi G; Ruoff KL; Hebert WP; O'Toole GA; Mastoridis P
PLoS One; 2015; 10(10):e0141192. PubMed ID: 26506004
[TBL] [Abstract][Full Text] [Related]
9. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
[TBL] [Abstract][Full Text] [Related]
10. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
[TBL] [Abstract][Full Text] [Related]
11. Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System.
Price KE; Naimie AA; Griffin EF; Bay C; O'Toole GA
J Bacteriol; 2016 Jan; 198(2):237-47. PubMed ID: 26483523
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.
Yau YC; Ratjen F; Tullis E; Wilcox P; Freitag A; Chilvers M; Grasemann H; Zlosnik J; Speert D; Corey M; Stanojevic S; Matukas L; Leahy TR; Shih S; Waters V
J Cyst Fibros; 2015 Mar; 14(2):262-6. PubMed ID: 25453872
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Høiby N
BMC Med; 2011 Apr; 9():32. PubMed ID: 21463524
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.
Fernández-Barat L; Ciofu O; Kragh KN; Pressler T; Johansen U; Motos A; Torres A; Hoiby N
J Cyst Fibros; 2017 Mar; 16(2):222-229. PubMed ID: 27651273
[TBL] [Abstract][Full Text] [Related]
17. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
Hengzhuang W; Green K; Pressler T; Skov M; Katzenstein TL; Wu X; Høiby N
Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
[TBL] [Abstract][Full Text] [Related]
18. Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa.
Soren O; Rineh A; Silva DG; Cai Y; Howlin RP; Allan RN; Feelisch M; Davies JC; Connett GJ; Faust SN; Kelso MJ; Webb JS
J Antimicrob Chemother; 2020 Jan; 75(1):117-125. PubMed ID: 31682251
[TBL] [Abstract][Full Text] [Related]
19. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis.
Dales L; Ferris W; Vandemheen K; Aaron SD
Eur J Clin Microbiol Infect Dis; 2009 Oct; 28(10):1275-9. PubMed ID: 19575248
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
Kirby BD; Al Ahmar R; Withers TR; Valentine ME; Valentovic M; Long TE; Gaskins JR; Yu HD
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010865
[No Abstract] [Full Text] [Related]
[Next] [New Search]
